The DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
Chronic kidney disease
Open accessAbstract
Chronic kidney disease (CKD) is defined by persistent urine abnormalities, structural abnormalities or impaired excretory renal function suggestive of a loss of functional nephrons. The majority of patients with CKD are at risk of accelerated cardiovascular disease and death. For those who progress to end-stage renal disease, the limited accessibility to renal replacement therapy is a problem in many parts of the world. Risk factors for the development and progression of CKD include low nephron number at birth, nephron loss due to increasing age and acute or chronic kidney injuries caused by toxic exposures or diseases (for example, obesity and type 2 diabetes mellitus). The management of patients with CKD is focused on early detection or prevention, treatment of the underlying cause (if possible) to curb progression and attention to secondary processes that contribute to ongoing nephron loss. Blood pressure control, inhibition of the renin–angiotensin system and disease-specific interventions are the cornerstones of therapy. CKD complications such as anaemia, metabolic acidosis and secondary hyperparathyroidism affect cardiovascular health and quality of life, and require diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Self-citationChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,030
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationOrganoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · Nephron · doi:10.1159/000433566 · Cited by 3,515
Self-citation
Cited by
Kellum, J. A., Romagnani, P., Ashuntantang, G., Ronco, C., Zarbock, A., & Anders, H.-J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00284-z · Cited by 1,741
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Self-citationTrends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Self-citationKou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study
Nyberg, S. T., Batty, G. D., Pentti, J., Virtanen, M., Alfredsson, L., Fransson, E. I., Goldberg, M., Heikkilä, K., Jokela, M., Knutsson, A., et al. (2018) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30139-7 · Cited by 392
Gyurászová, M., Gurecká, R., Bábíčková, J., & Tóthová, Ľ. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5478708 · Cited by 322
Obesity and chronic kidney disease
Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2022 · Cited by 267
Diverse Role of TGF-β in Kidney Disease
Gu, Y.-Y., Liu, X.-S., Huang, X.-R., Yu, X.-Q., & Lan, H.-Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00123 · Cited by 257
Li, S., Lin, Q., Shao, X., Zhu, X., Wu, J., Wu, B., Zhang, M., Zhou, W., Zhou, Y., Jin, H., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.12.005 · Cited by 112
Psoriasis and Systemic Inflammatory Disorders
Tashiro, T., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084457 · Cited by 104
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
Sehgal, R., Markov, Y., Qin, C., Meer, M., Hadley, C., Shadyab, A. H., Casanova, R., Manson, J. E., Bhatti, P., Moore, A. Z., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00958-3 · Cited by 79
Kibria, G. M. A., & Crispen, R. (2020) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2020.101193 · Cited by 64
Zhang, X., Tian, L., Majumdar, A., & Scheller, E. L. (2024) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2024.tb00300.x · Cited by 18
Chronic Kidney Disease and Coenzyme Q10 Supplementation
Hargreaves, I., Mantle, D., & Milford, D. (2019) · Journal of Kidney Care · doi:10.12968/jokc.2019.4.2.82 · Cited by 12
Emerging epigenetic modifications in renal fibrosis: From mechanisms to treatments
Suo, X., Ge, Q., Peng, L., Zhu, Q., Zhang, M., Cheng, X., Wang, F., Jin, J., Wang, J., & Meng, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.012 · Cited by 8
Ibos, K. E., Bodnár, É., Dinh, H., Kis, M., Márványkövi, F., Kovács, Z. Z. A., Siska, A., Földesi, I., Galla, Z., Monostori, P., et al. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-023-02884-y · Cited by 8
Metadata
- Authors
- Romagnani, P., Remuzzi, G., Glassock, R., Levin, A., Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & Anders, H.-J.
- Venue
- Nature Reviews Disease Primers
- Published
- 2017-11-23
- Volume
- 3
- Issue
- 1
- Pages
- 17088-17088
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4211210745
- Cited by
- 996
- References
- 230
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.